<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-11 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-11</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-11</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>thymoma_subtype_and_stage</strong></td>
                        <td>str</td>
                        <td>Thymoma classification details used in the study (e.g., WHO subtype A/AB/B1/B2/B3, thymic carcinoma, Masaoka-Koga stage), and any notes on histology (e.g., lymphocyte-rich, medullary features).</td>
                    </tr>
                    <tr>
                        <td><strong>autoimmune_phenotype</strong></td>
                        <td>str</td>
                        <td>Specific autoimmune/paraneoplastic syndromes reported in thymoma patients (e.g., myasthenia gravis, pure red cell aplasia, autoimmune cytopenias, thyroiditis, SLE-like disease, pemphigus, encephalitis, myocarditis, etc.), including whether multiple autoimmune diseases co-occur.</td>
                    </tr>
                    <tr>
                        <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                        <td>str</td>
                        <td>Any quantitative data on prevalence/incidence of autoimmunity in thymoma cohorts and/or effect sizes (odds ratios, hazard ratios), including denominators and comparison groups (e.g., thymic carcinoma, general population, non-thymoma MG).</td>
                    </tr>
                    <tr>
                        <td><strong>central_tolerance_defect_evidence</strong></td>
                        <td>str</td>
                        <td>Evidence of impaired central tolerance/negative selection in thymoma (e.g., reduced AIRE/FEZF2 expression, altered medullary thymic epithelial cell markers, decreased tissue-restricted antigen expression, abnormal MHC expression, defective antigen presentation machinery), including assays used (IHC, RNA-seq, qPCR).</td>
                    </tr>
                    <tr>
                        <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                        <td>str</td>
                        <td>Findings about thymocyte development/selection and the peripheral T-cell compartment (e.g., export of naïve/autoreactive T cells, abnormal CD4/CD8 proportions, TCR repertoire skewing, clonality, self-reactive signatures, changes in recent thymic emigrants), including methods (flow cytometry, TCR-seq).</td>
                    </tr>
                    <tr>
                        <td><strong>regulatory_T_cell_findings</strong></td>
                        <td>str</td>
                        <td>Reported changes in Tregs (e.g., FOXP3+ cell counts in tumor/periphery, suppressive function assays, cytokine profiles, CTLA-4, IL-2 axis), and whether changes correlate with autoimmune manifestations.</td>
                    </tr>
                    <tr>
                        <td><strong>B_cell_and_autoantibody_findings</strong></td>
                        <td>str</td>
                        <td>Autoantibodies and B-cell abnormalities linked to thymoma autoimmunity (e.g., AChR antibodies, striational antibodies like titin/ryanodine receptor, cytokine autoantibodies, ANA), as well as intratumoral germinal centers or plasma cells if described.</td>
                    </tr>
                    <tr>
                        <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                        <td>str</td>
                        <td>Evidence for combined immunodeficiency in thymoma patients (Good syndrome: hypogammaglobulinemia, low/absent B cells, infections), and any discussion of how immunodeficiency coexists with autoimmunity.</td>
                    </tr>
                    <tr>
                        <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                        <td>str</td>
                        <td>Tumor microenvironment signals implicated in immune dysregulation (e.g., cytokines/chemokines, checkpoint molecules, inflammatory signatures, epithelial cell pathways), including whether these signals are proposed to alter thymocyte education or peripheral tolerance.</td>
                    </tr>
                    <tr>
                        <td><strong>genetic_and_molecular_associations</strong></td>
                        <td>str</td>
                        <td>Host or tumor genetics/molecular alterations associated with autoimmunity (e.g., HLA associations, somatic mutations, copy number changes, epigenetic regulation, AIRE pathway alterations), and the direction/strength of association if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>clinical_correlates_and_temporality</strong></td>
                        <td>str</td>
                        <td>Clinical evidence about timing and correlation: whether autoimmunity precedes thymoma diagnosis, appears concurrently, or develops after; impact of thymectomy, tumor recurrence, or immunotherapy; correlations with subtype/stage/tumor burden.</td>
                    </tr>
                    <tr>
                        <td><strong>interventions_and_response_patterns</strong></td>
                        <td>str</td>
                        <td>Reported effects of treatments on autoimmune manifestations (e.g., thymectomy, steroids, IVIG, plasmapheresis, rituximab, cyclosporine), including response/relapse patterns and whether they inform mechanism.</td>
                    </tr>
                    <tr>
                        <td><strong>mechanistic_hypotheses_proposed</strong></td>
                        <td>str</td>
                        <td>Explicit mechanistic explanations proposed by the authors for high autoimmunity rates in thymoma (summarize in 1–3 sentences), including any causal chain (e.g., tumor disrupts medullary selection → autoreactive T-cell export → autoantibody production).</td>
                    </tr>
                    <tr>
                        <td><strong>key_supporting_results</strong></td>
                        <td>str</td>
                        <td>The most relevant results supporting the mechanism(s), with key numbers where available (e.g., fold-changes, p-values, proportions), stated concisely.</td>
                    </tr>
                    <tr>
                        <td><strong>counterevidence_and_alternative_explanations</strong></td>
                        <td>str</td>
                        <td>Any negative results, conflicting findings, or alternative interpretations (e.g., no AIRE difference, autoimmunity not correlated with subtype, effects attributed to treatment or detection bias).</td>
                    </tr>
                    <tr>
                        <td><strong>study_design_and_population</strong></td>
                        <td>str</td>
                        <td>Study type and population (e.g., case series, cohort, case-control, mechanistic tumor profiling, animal model), sample sizes (N thymoma, N controls), and key inclusion criteria (e.g., thymoma with/without MG).</td>
                    </tr>
                    <tr>
                        <td><strong>evidence_strength_limitations</strong></td>
                        <td>str</td>
                        <td>Main limitations relevant to causal inference (e.g., small N, confounding by MG, selection bias, lack of longitudinal data, lack of functional validation).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>